Literature DB >> 29736804

Influence of Fatty Acid Modification on Uptake of Lovastatin-Loaded Reconstituted High Density Lipoprotein by Foam Cells.

Yun Yang1, Ji Wang1,2, Hongliang He1, Wenli Zhang3, Yuansheng Zhang1, Jianping Liu4.   

Abstract

PURPOSE: Spherical reconstituted high density lipoprotein (rHDL) can target atherosclerotic lesions by the very low density lipoprotein (VLDL) receptor, which is seldom expressed in liver. By promoting this pathway, the targeting efficiency was hyphothesized to be improved due to avoiding undesired uptake in liver mediated by the scavenger receptor class B type I (SR-BI). In this study, how fatty acid modification in spherical rHDL influenced the VLDL receptor-mediated endocytosis pathway was investigated.
METHODS: Stearic acid (SA) and arachidonic acid (AA) with different saturation levels were utilized to modify the lovastatin-loaded rHDL (LS-rHDL). Phagocytosis test on foam cells with or without cholesteryl ester transfer protein (CETP) expression was conducted to observe the cellular uptake of the SA or AA modified rHDL and the non-modified one. Raman spectroscopy, guanidine hydrochloride (Gdn-HCl) denaturation experiment and in vitro evaluation of drug release were used to analyze the related mechanism.
RESULTS: In comparison with the non-modified rHDL, AA modification could reduce the packing order of the rHDL phospholipid acyl chains, leading to the decreased apoA-I binding extent with lipid and the increased drug release, while the opposite was true for SA modification. The AA-modified rHDL exhibited a higher uptake of foam cells expressing CETP than the non-modified one, while the SA-modified one showed the lowest cellular uptake among the three rHDLs.
CONCLUSIONS: Increased unsaturation level can facilitate lipid-interchange process where the cargo in rHDL core may transfer to VLDL more easily, and then promote the endocytosis mediated by the VLDL receptor.

Entities:  

Keywords:  fatty acid; lipid-interchange process; saturation level; spherical rHDL; very low density lipoprotein

Mesh:

Substances:

Year:  2018        PMID: 29736804     DOI: 10.1007/s11095-018-2419-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  45 in total

1.  Functions of cholesterol ester transfer protein and relationship to coronary artery disease risk.

Authors:  Alan R Tall
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

2.  Evidence of macrophage foam cell formation by very low-density lipoprotein receptor: interferon-gamma inhibition of very low-density lipoprotein receptor expression and foam cell formation in macrophages.

Authors:  S Kosaka; S Takahashi; K Masamura; H Kanehara; J Sakai; G Tohda; E Okada; K Oida; T Iwasaki; H Hattori; T Kodama; T Yamamoto; I Miyamori
Journal:  Circulation       Date:  2001-02-27       Impact factor: 29.690

Review 3.  ATP-binding cassette transporter A1 and HDL metabolism: effects of fatty acids.

Authors:  Jiyoung Lee; Youngki Park; Sung I Koo
Journal:  J Nutr Biochem       Date:  2011-06-17       Impact factor: 6.048

4.  Effect of fatty acids on phase behavior of hydrated dipalmitoylphosphatidylcholine bilayer: saturated versus unsaturated fatty acids.

Authors:  T Inoue; S Yanagihara; Y Misono; M Suzuki
Journal:  Chem Phys Lipids       Date:  2001-02       Impact factor: 3.329

5.  Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.

Authors:  C W Rittershaus; D P Miller; L J Thomas; M D Picard; C M Honan; C D Emmett; C L Pettey; H Adari; R A Hammond; D T Beattie; A D Callow; H C Marsh; U S Ryan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-09       Impact factor: 8.311

Review 6.  The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor.

Authors:  Sadao Takahashi; Juro Sakai; Takahiro Fujino; Hiroaki Hattori; Yasuo Zenimaru; Jinya Suzuki; Isamu Miyamori; Tokuo T Yamamoto
Journal:  J Atheroscler Thromb       Date:  2004       Impact factor: 4.928

7.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.

Authors:  Gregory J R Charrois; Theresa M Allen
Journal:  Biochim Biophys Acta       Date:  2004-05-27

8.  Colloidal Instability Fosters Agglomeration of Subvisible Particles Created by Rupture of Gels of a Monoclonal Antibody Formed at Silicone Oil-Water Interfaces.

Authors:  Shyam B Mehta; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2016-07-13       Impact factor: 3.534

9.  A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation.

Authors:  Raphaël Duivenvoorden; Jun Tang; David P Cormode; Aneta J Mieszawska; David Izquierdo-Garcia; Canturk Ozcan; Maarten J Otten; Neeha Zaidi; Mark E Lobatto; Sarian M van Rijs; Bram Priem; Emma L Kuan; Catherine Martel; Bernd Hewing; Hendrik Sager; Matthias Nahrendorf; Gwendalyn J Randolph; Erik S G Stroes; Valentin Fuster; Edward A Fisher; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

10.  pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy.

Authors:  Jae-Yoon Shin; Yoosoo Yang; Paul Heo; Ji-Chun Lee; Byoungjae Kong; Jae Youl Cho; Keejung Yoon; Cheol-Su Shin; Jin-Ho Seo; Sung-Gun Kim; Dae-Hyuk Kweon
Journal:  Int J Nanomedicine       Date:  2012-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.